

Statement on Louisiana Mifepristone Case (*LA v. FDA*, Court Grants Stay) - February 2026

Reproductive Futures

This decision from a federal court in Louisiana keeps access to telemedicine abortion available. While access is preserved for now, the FDA is continuing its review of mifepristone. The agency could make a decision not grounded in science or decades of evidence, but instead based on anti-abortion efforts to restrict access—particularly because telemedicine has proven so successful in reaching patients in states with limited access to care.

Reproductive Futures will continue to fight to preserve access to mifepristone and telemedicine abortion. Our legal advocacy and public education helps ensure reproductive healthcare remains safe, accessible, and grounded in science.

— *Julie F. Kay, JD, Founder and Executive Director, Reproductive Futures*